You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
啟明醫療-B(02500.HK):收購MITRALTECH股權交割完成
格隆匯 01-26 08:06

格隆匯1月26日丨啟明醫療-B(02500.HK)發佈公吿,有關公司通過收購Cardiovalve的母公司Mitraltech的股權及認購可換股貸款的方式,收購Cardiovalve 100%的股權。收購已於2022年1月25日完成。Cardiovalve現已成為公司間接全資附屬公司。

根據披露,Cardiovalve成立於2010年,總部設於以色列。其自主研發的Cardiovalve系統是一款同時可治療二尖瓣反流和三尖瓣反流的經導管介入瓣膜置換創新系統。與同類產品相比,其經股靜脈的入路方式顯着提升了治療安全性,其55mm的大瓣環設計適用約95%的患者羣體,同時,獨特的短瓣架設計可有效降低左室流出道梗阻風險。

目前,Cardiovalve系統正在美國和歐洲進行多中心臨牀試驗,初步臨牀效果良好。在二尖瓣反流的治療已在歐洲進入臨牀研究階段,並在美國進入早期可行性研究階段。此外,在三尖瓣反流的治療,Cardiovalve於2020年1月獲美國FDA授予的“突破性設備”稱號,並已進入早期可行性研究。Cardiovalve是首家獲得美國FDA批准,同時進行二尖瓣反流及三尖瓣反流適應症早期可行性研究的公司。

董事會深信,Cardiovalve與公司現有產品佈局具有顯着的協同效應,有助於鞏固公司在中國乃至全球結構性心臟病領域的領先地位。同時,Cardiovalve系統的引入將助推公司的國際化創新步伐,為未來進入國際主流市場打下堅實基礎。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account